# DoD Faces Nevada Ketamine Manufacturing Risk

The Department of Defense awarded iX Biopharma a nearly **$41 million** noncompetitive contract in February 2026 to develop Wafermine, a ketamine product for battlefield pain management, with U.S. manufacturing required. The proposed manufacturer, Orion Specialty Labs, has not received the Nevada pharmacy license it needs to operate; its next opportunity to seek approval is in early December 2026. The licensing issue creates a schedule risk for the manufacturing plan, though the signal does not establish that the contract schedule has formally changed.

- Contractors pursuing defense medical-product work should account for state facility licensing as a potential dependency in domestic manufacturing plans and schedules.
- Procurement teams can evaluate the award’s manufacturing-readiness and schedule risks alongside the stated U.S. production requirement; Orion’s next opportunity to seek Nevada approval is in early December.
- iX Biopharma’s Chief Commercial Officer said, “currently working through the various requirements and conditions relating to manufacturing and supply, and no final arrangements have been confirmed at this stage.”

**Jurisdictions:** federal
**Industries:** Defense & Military, Healthcare
**Topics:** Regulatory Compliance
**Published:** October 20, 2026

### Government Entities
- U.S. Department of Defense (DoD)
- Nevada Board of Pharmacy

### Vendors
- iX Biopharma (awardee)
- Orion Specialty Labs LLC (proposed manufacturer)

### Key Quotes
> currently working through the various requirements and conditions relating to manufacturing and supply, and no final arrangements have been confirmed at this stage.
> — Eva Tan, Chief Commercial Officer, iX Biopharma

### Sources
- [DOD ketamine contractor hits manufacturing snag - POLITICO](https://www.politico.com/newsletters/prescription-pulse/2026/10/20/dod-ketamine-contractor-hits-manufacturing-snag-01127373) - Politico